Daiichi Sankyo and AstraZeneca are padding the case for their antibody-drug conjugate Enhertu with new data demonstrating the medicine’s worth in patients whose cancer has spread to the brain.

Drugmakers at the top of the list were Astellas, AstraZeneca, Daiichi Sankyo, Gilead Sciences and Novartis. The five companies accounted for 71% of the high-benefit approvals over the past four years.

Just over a decade after being acquired by Daiichi Sankyo, US biotech Plexxikon will be shuttered at the end of March, with its R&D projects transferred to other areas of the Japanese group. It's ...

AstraZeneca and Daiichi Sankyo have moved swiftly to file for FDA approval of a second indication for their TROP2-directed antibody-drug conjugate datopotamab deruxtecan (Dato-DXd), this time for ...

As another major quake struck Japan, the country was still reckoning with the nuclear crisis triggered by the 8.9-magnitude earthquake and a tsunami of 13 years ago. By Emma Bubola By exaggerating ...

Daiichi Sankyo has made a little bit of pharma industry history, becoming the first drugmaker to win approval in Japan for a therapy for cancer based on a virus that selectively kills malignant cells.

There has been another twist in the road for the ongoing legal battle between Seagen and Daiichi Sankyo over patent rights for antibody-drug conjugate (ADC) Enhertu. The US Patent and Trademark ...

A US jury has decided that Daiichi Sankyo and AstraZeneca's breast cancer drug Enhertu infringes a patent held by US biotech Seagen, awarding almost $42 million in damages. Seagen claims Enhertu ( ...

Daiichi Sankyo has launched its oncolytic virus therapy Delytact in Japan – its first world market – as a treatment for malignant glioma, an aggressive form of brain cancer. Delytact ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Daiichi Sankyo’s Vanflyta has become the first drug in the US to be approved for newly-diagnosed acute myeloid leukaemia (AML) with FLT3-ITD mutations, nearly four years after being rejected by ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...